These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2384903)

  • 1. Effect of non-linear plasma protein binding on unbound and total plasma phenylbutazone concentrations in cows.
    Boudinot FD; Williams RJ; Smith JA
    J Vet Pharmacol Ther; 1990 Jun; 13(2):132-6. PubMed ID: 2384903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of phenylbutazone in beef steers.
    de Veau IF; Pedersoli W; Cullison R; Baker J
    J Vet Pharmacol Ther; 2002 Jun; 25(3):195-200. PubMed ID: 12081615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of phenylbutazone on thiamylal disposition and anaesthesia in ponies.
    Young DB; Ewing PJ; Burrows GE; Lessley BA; Clarke CR; Shawley RV
    J Vet Pharmacol Ther; 1994 Oct; 17(5):389-93. PubMed ID: 7853465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows.
    De Veau EJ; Pedersoli W; Cullison R; Baker J
    J Vet Pharmacol Ther; 1998 Dec; 21(6):437-43. PubMed ID: 9885966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentration, mammary excretion and side-effects of phenylbutazone after repeated oral administration in healthy cows.
    Martin K; Andersson L; Stridsberg M; Wiese B; Appelgren LE
    J Vet Pharmacol Ther; 1984 Jun; 7(2):131-8. PubMed ID: 6748155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary studies of offspring exposure to phenylbutazone and ivermectin during the perinatal period in a Holstein cow-calf model.
    Chamberlain PL; Fowler BA; Sexton MJ; Peggins JO; Bredow Jv
    Toxicol Appl Pharmacol; 2003 Mar; 187(3):198-208. PubMed ID: 12662903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients.
    Higham C; Aarons L; Holt PJ; Lynch M; Rowland M
    Br J Clin Pharmacol; 1981 Aug; 12(2):123-9. PubMed ID: 7306426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
    Karim A
    J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing.
    Williams RJ; Boudinot FD; Smith JA; Knight AP
    Am J Vet Res; 1990 Mar; 51(3):371-5. PubMed ID: 2316912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylbutazone in racing greyhounds: plasma and urinary residues 24 and 48 hours after a single intravenous administration.
    Mills PC; Ng JC; Skelton KV; Seawright AA; Auer DE
    Aust Vet J; 1995 Aug; 72(8):304-8. PubMed ID: 8579562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of phenylbutazone on the plasma disposition of penicillin G in the horse.
    Firth EC; Nouws JF; Klein WR; Driessens F
    J Vet Pharmacol Ther; 1990 Jun; 13(2):179-85. PubMed ID: 2384909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of antipyrine, phenylbutazone and phenytoin in experimental renal failure.
    Van Peer AP; Belpaire FM; Rosseel MT; Bogaert MG
    Pharmacology; 1981; 22(2):139-45. PubMed ID: 7208595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration.
    Lees P; Ayliffe T; Maitho TE; Taylor JB
    Res Vet Sci; 1988 Jan; 44(1):57-67. PubMed ID: 3375589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The concentration changes of different phenylbutazone formulations in horse plasma].
    Keller H; Hashem A
    Dtsch Tierarztl Wochenschr; 1996 Jun; 103(6):224-30. PubMed ID: 8766906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphenylhydantoin potency and plasma protein binding.
    Shoeman DW; Azarnoff DL
    J Pharmacol Exp Ther; 1975 Oct; 195(1):84-6. PubMed ID: 1181407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenylbutazone: plasma concentrations and effectiveness in patients with rheumatoid arthritis.
    Orme ML
    J Int Med Res; 1977; 5 Suppl 2():40-7. PubMed ID: 913873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies.
    Maitho TE; Lees P; Taylor JB
    J Vet Pharmacol Ther; 1986 Mar; 9(1):26-39. PubMed ID: 3701913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-binding high-performance frontal analysis of (R)- and (S)-warfarin on HSA with and without phenylbutazone.
    He J; Shibukawa A; Tokunaga S; Nakagawa T
    J Pharm Sci; 1997 Jan; 86(1):120-5. PubMed ID: 9002471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and analysis of unbound drug concentrations.
    Wright JD; Boudinot FD; Ujhelyi MR
    Clin Pharmacokinet; 1996 Jun; 30(6):445-62. PubMed ID: 8792057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys.
    Mealey KL; Matthews NS; Peck KE; Ray AC; Taylor TS
    Am J Vet Res; 1997 Jan; 58(1):53-5. PubMed ID: 8989496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.